Yüklüyor......
State-of-the-art pharmacological approaches to reduce chorea in Huntington’s Disease
INTRODUCTION: Chorea is a common motor manifestation of Huntington’s disease (HD). Two vesicular monoamine transporter type 2 (VMAT-2) inhibitors have been approved by the FDA for treatment of HD chorea, and a third is currently being assessed in a phase 3 trial. Antipsychotic therapies are used off...
Kaydedildi:
| Yayımlandı: | Expert Opin Pharmacother |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8222076/ https://ncbi.nlm.nih.gov/pubmed/33550875 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14656566.2021.1876666 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|